Top 10 API Pharma Companies in India

The API Companies in India traditionally been dominated by anti-infectives and diabetes, cardiovascular, analgesics and pain management drugs and simple molecules to becoming the preferred destination for high value and complex APIs.

To view top all pharma companies use the link: List of all Pharma Companies In India

The Indian pharmaceutical industry is the world’s third largest in terms of volume and ranks 11th in
terms of value. It is among the faster-growing markets and the largest exporter of generic drugs by volume

The Indian Pharma industry right from APIs to finished dosage formulation is well poised to grow and the Government has announced the production-linked incentive (PLI) scheme and has been
moving actively towards scaling the domestic manufacture of APIs/KSMs.

Sun Pharmaceutical Industries Limited

• Founded: 1983
• Headoffice: Mumbai
• Listed in Exchange: NSE(SUNPHARMA), BSE(524715)
• Industry: PHARMACEUTICALS
• website: sunpharma.com/india/

Sun pharma company profile:

Sun Pharmaceutical Industries is formally known as Sun Pharma, they are the fourth largest specialty generic and API pharma companies in the world.

Sun Pharma has manufacturing capabilities for a variety of dosage forms, such as injectables, sprays, ointments, creams, liquids, hormones, drug delivery systems, tablets, and capsules.

Sun Pharma always focused on both organic and inorganic growth, with the proactive acquisition of
businesses and in-licensing of specialty molecules.

Sun Pharma is the largest pharmaceutical company in the domestic market with an 8.17% market share and strong positioning in the high-growth chronic segments.

Their product portfolio includes generics, branded generics, specialty products, over the counter
(OTC) products, Active Pharmaceutical Ingredients (APIs), and intermediates.

Sun Pharmaceutical Industries Limited is a public limited company incorporated and domiciled in India. Sun pharma is listed on the BSE Limited and NSE Limited.

• Sun parma Product list
• Sun pharma contact details: PH: (+91 22) 4324 4324

Sun pharma Financial Analysis:

• Revenue from operation: 334,981.4 million
• Profit before tax: 27,993.7 million
• Profit of the year FY21: 29,038.2 million

• FY22: Nine-month statement
  • Revenue from operation: 290,403.4 million
  • Profit before tax: 65,569.2 million
  • Profit of year: 55,499.8 million

The Key ratio of Sun pharma

• Return on Net Worth (%): 6.2%
• Debtors Turnover: 3.7
• Inventory Turnover: 1.0
• Interest Coverage Ratio: 51.2
• Current Ratio: 1.9
• Debt Equity Ratio: 0.08
• Operating Profit Margin (%): 24.5%
• Net Profit Margin (%): 8.8%

Cadila Healthcare Limited

• Founded: 1952
• Headoffice: Ahmedabad
• Listed in Exchange: NSE(CADILAHC), BSE(532321)
• Industry: PHARMACEUTICALS
• website: www.zyduscadila.com

Cadila Healthcare company profile:

Cadila Healthcare Ltd. is one of the leading API pharma companies in India with a presence across
the pharmaceutical value chain of innovating research & development, manufacturing, marketing.

Cadila selling of finished dosage human formulations (generics, branded generics, and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (“APIs”), animal healthcare products, and consumer wellness products.

Cadila has a performance of different therapies, Gynaecological, Anti-diabetic, Anti-infective, and Pain Management portfolio grew better than the market.

Cadila APIs and intermediates business continued to support the formulations business as it ensured the supply of materials to the formulations plants in a timely and cost-efficient manner.

Cadila product

Cadila healthcare subsidiary:

Cadila has 15 Indian subsidiary companies, 26 foreign subsidiary companies, and 3 joint venture companies as of March 31, 2021.

1. Zydus Healthcare Limited, 2. German Remedies Pharmaceuticals Private Limited, 3. Zydus Wellness Limited, 4. Zydus Wellness Products Limited, 5. Liva Nutrition Limited, 6.Liva Investment Limited, 7. Zydus Animal Health and Investments Limited, 8.Dialforhealth Unity Limited, 9. Dialforhealth Greencross Limited, 10. Violio Healthcare Limited, 11.Zydus Pharmaceuticals Limited, 12.Biochem Pharmaceutical Private Limited, 13. Zydus Strategic Investments Limited, 14.Zydus Foundation, 15. Zydus VTEC Limited.

Cadila Healthcare Fundamentals

FY21:

• Revenue from operation: 151,022 million
• Profit before tax: 22,848 million
• Profit of the year: 21,850 million

FY22 Nine-month statement:

• Revenue from operation: 56,708 million
• Profit before tax: 8,174 million
• Profit of the year: 6,110 million

Aurobindo Pharma Limited

• Founded: 1986
• Headoffice: Hyderabad 
• Listed in Exchange: NSE(AUROPHARMA), BSE(524804)
• Industries: PHARMACEUTICALS
• website: www.aurobindo.com

Aurobindo Pharma company profile:

Aurobindo Pharma Limited is formally known as Aurobindo Pharma. they are a leading global API pharma companies and manufacturing generic formulations and Active Pharmaceutical Ingredients (API).

Aurobindo is a large vertically integrated company, focused on developing complex and difficult-to-manufacture pharmaceutical products for the global markets.

Aurobindo pharma has 27 manufacturing and packing facilities for its API and formulations business, which has the requisite approval from global regulatory authorities such as US FDA, EDQM, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil, etc.

Especially in APIs has 11 high specification manufacturing plants approved by key regulators and equipped with a site dedicated control laboratories in India.

Aurobindo pharma Financial analysis:

FY21:

• Revenue from operation: 158,236.8 million
• Profit before tax: 41,930.1 million
• Profit of the year: 31,129.1 million

FY22: Nine-month statement

• Revenue from operation: 17,64,612 lakhs
• Profit before tax: 2,77,911 lakhs
• Profit of the year: 2,07,097 lakhs

Key ratio:

• Net debt to Equity: (0.04)
• Return on Equity (ROE): 7.5
• Net debt to EBITDA:(0.15)
• Earnings per share: 23%

Cipla Limited

• Founded: 1935
• Headoffice: Mumbai
• Listed in Exchange: NSE(CIPLA), BSE(500087)
• Industry: PHARMACEUTICALS
• website: www.cipla.com

Cipla company profile:

Cipla Limited is one of the top API pharma companies in globally. In India, Cipla is involved in its business comprises branded prescription drugs, trade generics, and consumer health products.

Cipla Stand for Chemical Industrial & Pharmaceutical Laboratories Ltd and for Cipla product use the link https://www.cipla.com/our-offerings

Cipla’s product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.

50 years in manufacturing APIs, Cipla has produced more than 200 generics and complex APIs. Cipla’s dedicated 300+ strong team of scientists enable the Company to capably handle a wide range of chemistries and complex molecules.

Cipla Financial analysis:

• FY21:
  • Revenue from operation: 18,988.52 crores
  • Profit before tax: 3,290.06 crores
  • Profit of the year: 2,388.51 crores

• FY22 Nine-month statement
  • Revenue from operation: 16,399.42 crores
  • Profit before tax: 3,170.06 crores
  • Profit of the year: 2,154.68 crores

The key ratio of Cipla:

• Net Debt to EBITDA: -0.45
• Net Debt to Equity: (-0.10)
• Interest Coverage Ratio: 27
• Return on Equity (RoE): 14.1 %
• Earning per share: ₹ 26.71

Dr. Reddy’s Laboratories Limited

• Founded: 1986
• Headoffice: Telangana
• Listed in exchange: NSE(DRREDDY), BSE(500124)
• Industry: PHARMACEUTICALS
• website: www.drreddys.com
• Market Cap (₹ Lakhs): 70,04,426.42
• Contact details: +91 22 6280 1219, +91 22 7115 8120

Dr. Reddy’s Laboratories company profile;

Dr. Reddy’s laboratory is formally known as Dr.Reddy and they are an integrated pharmaceutical company globally and manufacturing, sales, and marketing operations span over 56 countries.

Dr.reddy business offers a portfolio of products and services that included Global Generics, Biologics, Active Pharmaceuticals Ingredients, Aurigene Pharmaceuticals services.

In API pharama companies is one of our core businesses for Dr.Reddy and partners
with several leading generic formulation companies in bringing their molecules first to the market.

Dr.Reddy has focused on innovation-led affordability gives customers access to the most complex active ingredients, while maintaining a consistent global quality standard.

Dr.reddy had 52 subsidiaries and one joint venture company

• Dr.reddy top 3 product manufacturing and services provider are
  • uprenorphine & Naloxone,
  • Omeprazole and
  • Nimesulide
• For Product details use the link drreddys.com/our-products/business-focus/

• Dr.reddy have 18 manufacturing units and six research and development facilities in India.
  • API Facilities there are 4 plant in Telugana and 2 in Andra Pradesh,
  • Formulation facilities there are 12 plants in Telugana, Andra Pradesh, Himachal Pradesh,

Dr.reddy Financial details:

FY21:

• Revenue from operation: 189,722 million
• Profit before tax: 26,413 million
• Profit of the year: 17,238 million

FY22: Nine-month statement

• Revenuefrom operation:160,023 million
• Profit before tax: 29,815 million
• Profit of the year: 22,693 million

The key ratio of Dr.reddy

• Net Debt/Equity: 0.04
• Current Ratio: 1.8
• Net Profit Margin: 9.1%
• Return on Net Worth: 10%

Divi’s Laboratories Limited

• Founded: 1990
• Headoffice: Telangana
• Listed in Exchange: NSE(DIVISLAB), BSE(532488)
• Industry: PHARMACEUTICALS
• website: www.divislabs.com
• Market Cap (₹ Lakhs): 1,11,88,173.30

Divi’s Laboratories company profile:

Divi’s Laboratories Limited is a leading manufacturer of API pharama companies in India and intermediates as well as nutraceutical ingredients offering quality products with a high level of compliance to customers in over 95 countries.

Divi has six multi-purpose manufacturing facilities from two sites with all support infrastructure like utilities, environment management, and safety systems.

Divi has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi’s
Laboratories Europe AG in Switzerland for marketing its nutraceutical products and to provide a greater reach to customers within these regions.

Divi’s product portfolio comprises two broad categories

1. Generic APIs (Active Pharma Ingredients) and Nutraceuticals
2. Custom Synthesis of APIs, intermediates and specialty ingredients for innovator pharma giants.
3. Divi’s product list use the link: www.divislabs.com/api-manufacturer-world/active-pharmaceutical-ingredients/generic-api-products/

Divi”s Financial analysis:

FY21:

• Revenue from operation: 6,79,861 lakhs
• Profit before tax: 2,62,787 lakhs
• Profit of the year: 1,95,472 lakhs

FY22: Nine-month statement

• Revenue from operation: 644139 lakhs
• Profit before tax: 260776 lakhs
• Profit of the year: 206581 lakhs

The key ratio of Divi’s Laboratories

• Return on Net Worth(%): 21.08%
• Return on Capital Employed (%): 34.69%
• Basic EPS: 73.63
• Debtors Turnover: 4.19
• Inventory Turnover: 3.62
• Current ratio: 5.63
• Debt Equity ratio: 0.00004
• Operating profit margin (%): 42.02%
• Net profit margin (%): 28.49%

Gland Pharma Limited

• Founded:1978
• Headoffice: Hyderabad 
• Listed in Exchange: NSE(GLAND), BSE(543245)
• Industry: Pharmaceuticals 
• Website: www,glandpharma.com
• Market capitalization: 55,04,141.22 lakhs
• Contact number:+91-40-30510999 | +91-8455-699999 |+91-7075736524

Gland Pharma company profile:

Gland Pharma is one of the fastest-growing generic injectables-focused and API pharma companies in India. they offer services that cover the entire injectables value-chain, including contract development, own development, dossier preparation and filing, technology transfer, and manufacturing across a range of delivery systems.

Gland Pharma has made substantial investments in its manufacturing infrastructure, with 8 manufacturing facilities in Southern India, comprising of 4 finished formulations facilities with a total of 23 production lines and four API facilities.

Gland Pharma sells its products primarily under a business-to-business (“B2B”) model in over 60 countries with its core markets being the United States, Europe, Canada, Australia, and India. For Product use the link: glandpharma.com/our_business/product

Gland Pharma Financial analysis:

• Revenue from operation: 34,629 million
• Profit before tax: 13,348 million
• Profit of the year: 9,970 million

FY22: for the nine-month statement

• Revenue from operation: 32,976.94 million
• Profit before tax: 12,380.68 million
• Profit of the year: 9,257.62 million

The key ratio of Gland Pharma

• Debtors turnover 5.16
• Inventory turnover 1.58
• Current ratio 4.13
• EBITDA margin 40%
• Net profit margin 28%
• Return on net worth 17%

Glenmark Pharmaceuticals Limited

• Founded: 1977
• Headoffice: Mumbai
• Listed in Exchange: NSE(GLENMARK), BSE(532296)
• Industry: Pharmaceuticals
• Website: glenmarkpharma
• Market capitalization: 55,04,141.22 lakhs

Genmark Pharmaceuticals company profile:

Glenmark Pharmaceuticals is a global, integrated, innovation-led API pharma companies, with a presence in the world’s major markets.

Genmark reorganized itself into three different entities: Glenmark Pharmaceuticals, Glenmark Life
Sciences and Ichnos Sciences. This restructuring is expected to place all three companies on an
accelerated growth trajectory.

Glenmark is one of the fastest-growing companies in the Indian Pharma market. The launch of innovative and differentiated products with successful brand building helped to reach 14 positions in the Indian pharma.

Nine of our brands are amongst the ‘Top 300 Brands’ in the Indian Pharmaceutical Market. This is the result of our focus on launching differentiated products in core areas, effectively utilizing our product selection, R&D, manufacturing skills, and extended reach through a strong sales force and market network.

Genmark Pharmaceutical financial analysis:

FY21:

• Revenue from operaation:109,439.29 million
• Profit before tax: 13,824.75 million
• Profit of the year: 9,700.88 million

FY22: Nine-month statement

• Revenue from operaation: 63,560.37 million
• Profit before tax: 21,126.63 million
• Profit of the year: 17,92.94 million

IPCA Laboratories Limited

• Founded: 1949
• Headoffice: Mumbai
• Listed in Exchange: NSE(IPCALAB), BSE(524494)
• Industry: Pharmaceutical
• website: ipca
• Market capitalization: 23,52,218.66 lakhs

IPCA Laboratories company profile:

IPCA Laboratories is a global API pharma companies, with creating healthy doses of life. IPCA is one of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally.

IPCA has produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

they have 15 APIs & 11 Formulations manufacturing facilities across the globe and top leading brands in Pain, Rheumatology, Antimalarials, and Haircare therapy in India

IPCA has branded formulations business in India now comprises of 16 marketing divisions focusing on key therapeutic segments with a portfolio of about 145 brands.

IPCA Laboratories financial statement:

FY21:

• Revenue from operation: 5,419.99 crores
• Profit before tax: 1,381.28 crores
• Profit of the year: 1,141.14 crores

FY22: Nine-month statement

• Revenue from operation: 4230.91 crores
• Profit before tax: 950.73 crores
• Profit of the year: 760.53 crores

The key ratio of IPCA

• Operating profit margin (%): 25.1%
• Net profit margin (%): 21.93%
• Debtors turnover ratio: 6.30
• Current ratio: 3.08
• Inventory turnover ratio: 2.77
• Debt Equity Ratio: 0.03
• Return on Net Worth (%): 24%

Alembic Pharmaceuticals Limited

• Founded: 1907
• Headoffice: Gujarat
• Listed in Exchange: NSE(APLLTD), BSE(533573)
• Industry: Pharmaceuticals
• website: alembicpharmaceuticals.com
• Market capitalization: 13,84,099.24 lakhs

Alembic Pharmaceuticals company profile:

Alembic Pharmaceutical is a vertically integrated API pharma companies committed to delivering high-quality healthcare for patients around the world.

Alembic is one of India’s oldest and leading pharmaceutical companies to manufacture formulations
and APIs for India and the global market.

Alembic products cater to 10 therapeutic areas in the domestic market and are known for on-time delivery to clients. Their enriching portfolio is owing to unparalleled research and development strengths, concentrated across our R&D facilities in Vadodara (Gujarat), Hyderabad (Telangana) and
New Jersey (USA).

• 3 Manufacturing faciities
  • Panelav
  • Karkhadi
  • Jarod

Developing APIs internally for selective formulation products with World-class facilities and adding
more capacities to cater future growth opportunities and API supplied to formulators in over 60 countries across the globe with FDA-approved facilities

Alembic Pharmaceuticals Financial analysis:

FY21:

• Revenue from operation: 5,393.13 crores
• Profit before tax: 1,368.08 crores
• Profit of the year: 1,146.50 crores

FY22: Nine-month statement

• Revenue from operation: 3,890.05 crores
• Profit before tax: 579.51 crores
• Profit of the year: 490.55 crores

The key ratio of Alembic Pharma

• Current ratio: 2.01
• Debt equity ratio:0.01
• Debt turnover ratio: 8.89
• Operating margin ratio: 2.6